Myocardial Metabolic Reprogramming in HFpEF

Area of Science:

• Cardiology
• Metabolic research
• Biochemistry

Background:

• Heart failure (HF) is a major global health burden, with HF with preserved ejection fraction (HFpEF) affecting over half of patients.
• Current HFpEF treatments primarily manage symptoms, lacking targeted therapies due to incomplete understanding of its mechanisms.
• Cardiac metabolic reprogramming is a compensatory response to stress in HF, but its specific role in HFpEF needs further investigation.

Purpose of the Study:

• To review the current understanding of cardiac mitochondrial dysfunction in HFpEF.
• To summarize the role of cardiac metabolic reprogramming in the pathophysiology of HFpEF.
• To highlight potential therapeutic strategies targeting metabolic pathways for HFpEF treatment.

Main Methods:

• Literature review focusing on cardiac metabolism and HFpEF.
• Synthesis of findings on mitochondrial function and metabolic shifts in HFpEF.
• Analysis of emerging therapeutic targets related to metabolic reprogramming.

Main Results:

• HFpEF is characterized by significant cardiac mitochondrial dysfunction.
• Metabolic reprogramming, including altered substrate utilization, is a key feature of HFpEF.
• These metabolic alterations contribute to pathological cardiac remodeling in HFpEF.

Conclusions:

• Mitochondrial dysfunction and metabolic reprogramming are central to HFpEF pathophysiology.
• Targeting metabolic pathways presents a novel and promising therapeutic avenue for HFpEF.
• Further research into metabolic interventions could lead to effective HFpEF treatments.